Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis has entered into a research pact with Harvard University to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange.
Subscribe to our email newsletter
The collaboration is focused on translational biomedical research in multiple therapeutic areas such as cancer, diabetes and inflammation.
The collaboration will support a number of activities over the term of the agreement through the granting of funding awards.
The funded projects will be selected by a Joint Scientific Steering Committee comprised of representatives of sanofi-aventis and Harvard, respectively.
Reportedly, the projects will be awarded funding based on their scientific merit and potential to generate translational insight and value to biomedical research.
Sanofi-aventis said that the collaboration provides the company with the opportunity to develop diagnostic, therapeutic and prognostic applications of discoveries made.
Sanofi-aventis Research & Development executive vice-president Marc Cluzel said that they are hopeful that promoting open scientific exchange between Harvard’s biological researchers and Sanofi-aventis’ drug development environment will drive significant healthcare advances.